Cross Country Healthcare (CCRN) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity Registrant Name	CROSS COUNTRY HEALTHCARE, INC
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001141103
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity File Number	0-33169
Entity Tax Identification Number	13-4066229
Entity Address, Address Line One	6551 Park of Commerce Boulevard, N.W.
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33487
City Area Code	561
Local Phone Number	998-2232
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	CCRN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,668,729,000

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 13,488	$ 1,600
Accounts receivable, net of allowances of $3,934 in 2021 and $4,021 in 2020	245,489	170,003
Prepaid expenses	5,430	5,455
Insurance recovery receivable	4,752	4,698
Other current assets	575	1,355
Total current assets	269,734	183,111
Property and equipment, net of accumulated depreciation of $17,774 in 2021 and $17,013 in 2020	13,026	12,351
Operating lease right-of-use assets	9,835	10,447
Goodwill	90,924	90,924
Trade names, indefinite-lived	5,900	5,900
Other intangible assets, net	33,341	34,831
Other non-current assets	19,593	19,409
Total assets	442,353	356,973
Current liabilities:
Accounts payable and accrued expenses	59,797	49,877
Accrued compensation and benefits	53,383	35,540
Operating lease liabilities - current	4,803	4,509
Other current liabilities	3,677	3,497
Total current liabilities	121,660	93,423
Revolving credit facility	96,025	53,408
Operating lease liabilities - non-current	13,978	15,234
Non-current deferred tax liabilities	6,858	6,592
Long-term accrued claims	24,624	25,412
Other long-term liabilities	5,534	7,995
Total liabilities	268,679	202,064
Commitments and contingencies
Stockholders' equity:
Common stock	4	4
Additional paid-in capital	309,711	310,388
Accumulated other comprehensive loss	(1,286)	(1,280)
Accumulated deficit	(135,289)	(154,737)
Total Cross Country Healthcare, Inc. stockholders' equity	173,140	154,375
Noncontrolling interest in subsidiary	534	534
Total stockholders' equity	173,674	154,909
Total liabilities and stockholders' equity	$ 442,353	$ 356,973

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 3,934	$ 4,021
Property and equipment, accumulated depreciation	$ 17,774	$ 17,013

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:ServiceMember	us-gaap:ServiceMember
Revenue from services	$ 329,241	$ 210,064
Operating expenses:
Direct operating expenses	257,776	160,461
Selling, general and administrative expenses	46,327	45,881
Bad debt expense	504	539
Depreciation and amortization	2,253	3,296
Acquisition and integration-related costs	0	77
Restructuring costs	1,238	564
Impairment charges	149	0
Total operating expenses	308,247	210,818
Income (loss) from operations	20,994	(754)
Other expenses (income):
Interest expense	671	867
Other income, net	(37)	(31)
Income (loss) before income taxes	20,360	(1,590)
Income tax expense	912	178
Consolidated net income (loss)	19,448	(1,768)
Less: Net income attributable to noncontrolling interest in subsidiary	0	321
Net income (loss) attributable to common shareholders	$ 19,448	$ (2,089)
Net income (loss) per share attributable to common shareholders - Basic (in dollars per share)	$ 0.54	$ (0.06)
Net income (loss) per share attributable to common shareholders - Diluted (in dollars per share)	$ 0.53	$ (0.06)
Weighted average common shares outstanding:
Basic (shares)	36,181	35,873
Diluted (shares)	37,034	35,873

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Consolidated net income (loss)	$ 19,448	$ (1,768)
Other comprehensive loss, before income tax:
Unrealized foreign currency translation loss	(6)	(78)
Taxes on other comprehensive loss:
Income tax effect related to unrealized foreign currency translation loss	0	0
Other comprehensive loss, net of tax	(6)	(78)
Comprehensive income (loss)	19,442	(1,846)
Less: Net income attributable to noncontrolling interest in subsidiary	0	321
Comprehensive income (loss) attributable to common shareholders	$ 19,442	$ (2,167)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss, net	(Accumulated Deficit) Retained Earnings	Noncontrolling Interest in Subsidiary
Beginning balance (in shares) at Dec. 31, 2019		35,871
Beginning balance at Dec. 31, 2019	$ 163,500	$ 4	$ 305,643	$ (1,240)	$ (141,775)	$ 868
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock (in shares)		221
Vesting of restricted stock	(635)		(635)
Equity compensation	927		927
Foreign currency translation adjustment, net of taxes	(78)			(78)
Distribution to noncontrolling shareholder	(544)					(544)
Net income (loss)	(1,768)				(2,089)	321
Ending balance (in shares) at Mar. 31, 2020		36,092
Ending balance at Mar. 31, 2020	161,402	$ 4	305,935	(1,318)	(143,864)	645
Beginning balance (in shares) at Dec. 31, 2020		36,177
Beginning balance at Dec. 31, 2020	154,909	$ 4	310,388	(1,280)	(154,737)	534
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock (in shares)		318
Vesting of restricted stock	(2,026)		(2,026)
Equity compensation	1,349		1,349
Foreign currency translation adjustment, net of taxes	(6)			(6)
Net income (loss)	19,448				19,448	0
Ending balance (in shares) at Mar. 31, 2021		36,495
Ending balance at Mar. 31, 2021	$ 173,674	$ 4	$ 309,711	$ (1,286)	$ (135,289)	$ 534

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Consolidated net income (loss)	$ 19,448	$ (1,768)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	2,253	3,296
Provision for allowances	1,095	881
Non-cash lease expense	622	1,191
Equity compensation	1,349	927
Other non-cash costs	629	174
Changes in operating assets and liabilities:
Accounts receivable	(76,581)	3,846
Prepaid expenses and other assets	568	(736)
Accounts payable and accrued expenses	26,507	11,066
Operating lease liabilities	(1,115)	(1,467)
Other	298	(248)
Net cash (used in) provided by operating activities	(24,927)	17,162
Cash flows from investing activities
Purchases of property and equipment	(1,186)	(962)
Net cash used in investing activities	(1,186)	(962)
Cash flows from financing activities
Borrowings under revolving credit facility	148,016	107,274
Repayments on revolving credit facility	(105,400)	(110,600)
Cash paid for shares withheld for taxes	(2,026)	(635)
Principal payments on note payable	(2,425)	0
Cash payments to noncontrolling shareholder	0	(544)
Other	(161)	(94)
Net cash provided by (used in) financing activities	38,004	(4,599)
Effect of exchange rate changes on cash	(3)	(34)
Change in cash and cash equivalents	11,888	11,567
Cash and cash equivalents at beginning of period	1,600	1,032
Cash and cash equivalents at end of period	$ 13,488	$ 12,599

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION Nature of Business The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company), as well as Cross Country Talent Acquisition Group, LLC, which was a joint venture controlled by the Company but not wholly-owned. Effective December 31, 2020, the sole pr ofessional staffing services agreement held by this joint venture was terminated and, as a result, the Company expects to dissolve Cross Country Talent Acquisition Group, LLC during fiscal 2021. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These adjustments consisted of all normal recurring items. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by United States generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K as filed with the SEC on February 25, 2021 (2020 Form 10-K). The December 31, 2020 condensed consolidated balance sheet included herein was derived from the December 31, 2020 audited consolidated balance sheet included in the 2020 Form 10-K. Certain prior year amounts have been reclassified to conform to the current year presentation. See condensed consolidated statements of cash flows, Note 3 - Revenue Recognition, and Note 11 - Segment Data.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context of the unknown future impacts of the current global outbreak of COVID-19 using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (1) the valuation of accounts receivable; (2) goodwill, trade names, and other intangible assets; (3) other long-lived assets; (4) share-based compensation; (5) accruals for health, workers’ compensation, and professional liability claims; (6) valuation of deferred tax assets; (7) legal contingencies; (8) income taxes; and (9) sales and other non-income tax liabilities. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates, including management's expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates. Accounts Receivable, net The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors’ time worked but not yet billed at March 31, 2021 and December 31, 2020 totaled $92.2 million and $48.3 million, respectively. The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable and contract assets based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered current expectations of future economic conditions, including the impact of COVID-19, when estimating its allowance for doubtful accounts. The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: Three Months Ended March 31, 2021 2020 Allowance for Doubtful Accounts (amounts in thousands) Balance at beginning of period $ 3,416 $ 2,406 Bad Debt Expense 504 539 Write-Offs, net of Recoveries (699) (349) Balance at end of period 3,221 2,596 In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The balance of this allowance as of March 31, 2021 and December 31, 2020 was $0.7 million and $0.6 million, respectively. The Company’s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are U.S. based healthcare systems with a significant percentage in acute-care facilities. No single customer accounted for more than 10% of the Company’s revenue for the three months ended March 31, 2021 and 2020, or the accounts receivable balance as of December 31, 2020. However, one Nurse and Allied Staffing customer represented approximately 12% of the Company's accounts receivable balance as of March 31, 2021. Restructuring Costs The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations primarily include employee termination costs and lease-related exit costs. Reconciliation of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below: Employee Termination Costs Lease-Related Exit Costs (amounts in thousands) Balance at January 1, 2021 $ 499 $ 2,687 Charged to restructuring costs (a) 824 46 Payments (344) (207) Balance at March 31, 2021 979 2,526 ________________ (a) Aside from what is presented in the table above, restructuring costs in the condensed consolidated statements of operations for the three months ended March 31, 2021 include $0.4 million of ongoing lease costs related to the Company's strategic reduction in its real estate footprint which are included as operating lease liabilities - current and non-current in our condensed consolidated balance sheets. Other costs were immaterial for the three months ended March 31, 2021. Recently Adopted Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The guidance requires either a prospective, retrospective, or modified retrospective approach depending on the amendment. The Company prospectively adopted this guidance with no material impact on its consolidated financial statements.

REVENUE RECOGNITION

REVENUE RECOGNITION	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue. Three Months ended March 31, 2021 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 305,975 $ 15,406 $ 321,381 Other Services 7,033 827 7,860 Total $ 313,008 $ 16,233 $ 329,241 Three Months ended March 31, 2020 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 184,949 $ 17,160 $ 202,109 Other Services 6,934 1,021 7,955 Total $ 191,883 $ 18,181 $ 210,064 ________________

COMPREHENSIVE INCOME (LOSS)

COMPREHENSIVE INCOME (LOSS)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
COMPREHENSIVE INCOME (LOSS)	COMPREHENSIVE INCOME (LOSS) Total comprehensive income (loss) includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes. Certain of the Company’s foreign subsidiaries use their respective local currency as their functional currency. In accordance with the Foreign Currency Matters Topic of the FASB ASC, assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of $1.3 million at March 31, 2021 and December 31, 2020. The income tax impact related to components of other comprehensive income (loss) for the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of comprehensive income (loss).

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended March 31, 2021 2020 (amounts in thousands, except per share data) Numerator: Net income (loss) attributable to common shareholders - Basic and Diluted $ 19,448 $ (2,089) Denominator: Weighted average common shares - Basic 36,181 35,873 Effect of diluted shares: Share-based awards (a) 853 — Weighted average common shares - Diluted 37,034 35,873 Net income (loss) per share attributable to common shareholders - Basic $ 0.54 $ (0.06) Net income (loss) per share attributable to common shareholders - Diluted $ 0.53 $ (0.06) ________________ (a) Due to the net loss for the three months ended March 31, 2020, 454,920 shares were excluded from diluted weighted average shares due to their anti-dilutive effect.

GOODWILL, TRADE NAMES, AND OTHE

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS	GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS The Company had the following acquired intangible assets: March 31, 2021 December 31, 2020 Gross Accumulated Net Gross Accumulated Net (amounts in thousands) Intangible assets subject to amortization: Databases $ 30,530 $ 16,085 $ 14,445 $ 30,530 $ 15,322 $ 15,208 Customer relationships 33,538 14,719 18,819 33,538 14,007 19,531 Non-compete agreements 304 227 77 304 212 92 Trade names — — — — — — Other intangible assets, net $ 64,372 $ 31,031 $ 33,341 $ 64,372 $ 29,541 $ 34,831 Intangible assets not subject to amortization: Trade names, indefinite-lived $ 5,900 $ 5,900 As of March 31, 2021, estimated annual amortization expense is as follows: Years Ending December 31: (amounts in thousands) 2021 $ 4,473 2022 5,933 2023 5,875 2024 5,238 2025 4,679 Thereafter 7,143 $ 33,341 The changes in the carrying amount of goodwill by reportable segment are as follows: Nurse and Physician Total (amounts in thousands) Balances as of December 31, 2020 Aggregate goodwill acquired $ 367,880 $ 43,405 $ 411,285 Sale of business (9,889) — (9,889) Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss 88,117 2,807 90,924 Balances as of March 31, 2021 Aggregate goodwill acquired 367,880 43,405 411,285 Sale of business (9,889) — (9,889) Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss $ 88,117 $ 2,807 $ 90,924 ________________ In the first quarter of 2021, the Company modified its reportable segments and, as a result, now discloses the following two reportable segments - Nurse and Allied Staffing and Physician Staffing. In the table above, goodwill balances and activity previously reported in the Search segment have been reclassified to Nurse and Allied Staffing. Goodwill, Trade Names, and Other Intangible Assets Impairment The Company tests reporting units’ goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances such as reporting units’ historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors, including COVID-19, and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed. As of March 31, 2021, the Company performed a qualitative assessment of each of its reporting units and determined it was not more likely than not that the fair value of its reporting units dropped below their carrying value. A lthough management believes that the Company's current estimates and assumptions utilized in its quantitative testing are reasonable and supportable, including its assumptions on the impact and timing related to COVID-19, there can be no assurance that the estimates and assumptions management used for purposes of its qualitative assessment as of March 31, 2021 will prove to be accurate predictions of future performance. For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. During the three months ended March 31, 2021, the Company wrote off a discontinued software development project, resulting in an immaterial impairment charge. Intangible Asset Amortization In connection with its rebranding efforts, the Company made a decision at the end of 2019 to phase out a trade name by the end of 2020, which as of December 31, 2019 would have been recognized over a weighted average life of 7.5 years. In connection with this decision, the Company recognized accelerated amortization related to the trade name of $2.9 million throughout 2020. Total accelerated amortization resulting from the changes in the estimated remaining life of the trade name was $0.7 million, or $0.02 per share for the three months ended March 31, 2020.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
DEBT	DEBT 2019 ABL Credit Agreement Effective October 25, 2019, the Company terminated its commitments under its prior senior credit facility entered into in August 2017 and entered into an ABL Credit Agreement (Loan Agreement). The Loan Agreement provides for a five-year revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $120.0 million (as described below), including a sublimit for swing loans up to $15.0 million and a $35.0 million sublimit for standby letters of credit. On June 30, 2020, the Company amended its Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0 million to $130.0 million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. On March 8, 2021, the Company amended its Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0 million to $150.0 million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers. These amendments were treated as modifications of debt and, as a result, the associated immaterial fees and costs were included in debt issuance costs and will be amortized ratably over the remaining term of the agreement. Availability of the ABL commitments is subject to a borrowing base of up to 85% of secured eligible accounts receivable, subject to adjustment at certain quality levels, plus an amount of supplemental availability, and reducing over time in accordance with the terms of the Loan Agreement, minus customary reserves, and subject to customary adjustments. Revolving loans and letters of credit issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. Availability under the ABL will be used for general corporate purposes. At March 31, 2021, availability under the ABL was $150.0 million and the Company had $96.0 million of borrowings drawn, as well as $18.5 million of letters of credit outstanding related to workers' compensation and professional liability policies, leaving $35.5 million available for borrowing. The balances drawn are presented as revolving credit facility on the condensed consolidated balance sheets and as of March 31, 2021 and December 31, 2020 had a weighted average interest rate of 2.46% and 2.73%, respectively. As of March 31, 2021, the interest rate spreads and fees under the Loan Agreement were based on LIBOR plus 2.00% for the revolving portion of the borrowing base and LIBOR plus 4.00% on the Supplemental Availability. The Base Rate (as defined by the Loan Agreement) margins would have been 1.00% and 3.00%, respectively, for the revolving portion and Supplemental Availability, respectively. The LIBOR and Base Rate margins are subject to monthly pricing adjustments, pursuant to a pricing matrix based on the Company’s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is 0.375% of the average daily unused portion of the revolving credit facility. The Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum fixed charge coverage ratio. The Company was in compliance with this covenant as of March 31, 2021. Obligations under the ABL are secured by substantially all the assets of the borrowers and guarantors, subject to customary exceptions. Note Payable In the first quarter of 2020, the Company entered into a note payable of $7.3 million related to contingent consideration assumed as part of a prior period acquisition, payable in three installments. The second installment of $2.4 million was paid in the first quarter of 2021, leaving a note payable balance of $2.5 million at March 31, 2021 which is included in other current liabilities on the condensed consolidated balance sheets.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
LEASES	LEASES The Company's lease population of its right-of-use asset and lease liabilities under the Leases Topic of the FASB ASC is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent months during the lease term and/or escalating rent payments and, particularly for the Company’s longer-term leases for its corporate offices, it has received incentives to enter into the leases such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions. Beginning in the second quarter of 2020, in connection with the continuing developments from COVID-19, the Company expedited restructuring plans and either reduced or fully vacated leased office space. The Company is in the process of seeking to sublet some of the space where possible. The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets: Classification on Condensed Consolidated Balance Sheets: March 31, 2021 December 31, 2020 (amounts in thousands) Operating lease right-of-use assets $ 9,835 $ 10,447 Operating lease liabilities - current $ 4,803 $ 4,509 Operating lease liabilities - non-current $ 13,978 $ 15,234 March 31, 2021 December 31, 2020 Weighted-average remaining lease term 3.9 years 4.1 years Weighted average discount rate 6.36 % 6.32 % The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2021: Years Ending December 31: (amounts in thousands) 2021 $ 4,413 2022 5,381 2023 5,048 2024 3,687 2025 2,716 Total minimum lease payments 21,245 Less: amount of lease payments representing interest (2,464) Present value of future minimum lease payments 18,781 Less: operating lease liabilities - current (4,803) Operating lease liabilities - non-current $ 13,978 Other Information The table below provides information regarding supplemental cash flows: Three Months Ended March 31, 2021 2020 (amounts in thousands) Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of operating lease liabilities $ 1,637 $ 1,835 Right-of-use assets acquired under operating lease $ — $ 500 The components of lease expense are as follows: Three Months Ended March 31, 2021 2020 (amounts in thousands) Amounts Included in Condensed Consolidated Statements of Operations: Operating lease expense $ 914 $ 1,523 Short-term lease expense $ 849 $ 1,845 Variable and other lease costs $ 468 $ 574 Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material. As of March 31, 2021, the Company does not have any material operating leases which have not yet commenced. The Company has an immaterial amount of finance lease contracts related to other equipment rentals which are not included in the above disclosures.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Fair Value Measurements and Disclosures Topic of the FASB ASC defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 —Quoted prices in active markets for identical assets or liabilities. Level 2 —Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Items Measured at Fair Value on a Recurring Basis: The Company’s financial assets/liabilities required to be measured on a recurring basis were its: (i) deferred compensation asset included in other non-current assets; and (ii) deferred compensation liability included in other long-term liabilities. Deferred compensation —The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company’s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents. The estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis is as follows: Fair Value Measurements March 31, 2021 December 31, 2020 (amounts in thousands) Financial Assets: (Level 1) Deferred compensation asset $ 1,204 $ 1,156 Financial Liabilities: (Level 1) Deferred compensation liability $ 2,553 $ 2,475 Items Measured at Fair Value on a Non-Recurring Basis: The Company's non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. Other Fair Value Disclosures: Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and accrued expenses approximate their carrying amount due to the short-term nature of these instruments. The Company paid the second installment on its note payable in the first quarter of 2021. The remaining balance is included in other current liabilities on the condensed consolidated balance sheets. Due to its relatively short-term nature, the carrying value of the note payable approximates its fair value. The carrying amount of the Company's ABL approximates fair value because the interest rates are variable and reflective of market rates. The carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value are as follows: March 31, 2021 December 31, 2020 Carrying Fair Carrying Fair Financial Liabilities: (amounts in thousands) (Level 2) Note Payable $ 2,426 $ 2,426 $ 4,851 $ 4,851 Senior Secured Asset-Based Loan $ 96,025 $ 96,025 $ 53,408 $ 53,408 Concentration of Credit Risk: See discussion of credit losses and allowance for doubtful accounts in Note 2 - Summary of Significant Accounting Policies. Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stock Repurchase Program During the three months ended March 31, 2021 and 2020, the Company did not repurchase any shares of its common stock. As of March 31, 2021, the Company has 510,004 shares of common stock under the current share repurchase program available to repurchase, subject to certain conditions in the Company's ABL Credit Agreement. Share-Based Payments On May 19, 2020, the Company's shareholders approved the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan), which replaced the 2017 Omnibus Incentive Plan (2017 Plan), and applies to awards granted after May 19, 2020. The remaining shares available for grant under the 2017 Plan were cancelled and no further awards will be granted under that plan. The 2020 Plan generally mirrors the terms of the 2017 Plan and includes the following provisions: (i) an aggregate share reserve of 3,000,000 shares; (2) annual dollar and share limits of awards granted to employees and consultants, as well as non-employee directors, based on type of award; (3) awards granted generally will be subject to a minimum one-year vesting schedule; and (4) awards may be granted under the 2020 Plan until March 24, 2030. The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the three months ended March 31, 2021: Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2021 1,345,819 $ 7.04 548,151 $ 7.64 Granted 384,871 $ 12.49 160,416 $ 12.49 Vested (479,793) $ 7.34 — $ — Forfeited (37,814) $ 6.95 (125,523) $ 10.24 Unvested restricted stock awards, March 31, 2021 1,213,083 $ 8.65 583,044 $ 8.41 Restricted stock awards granted under the Company’s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company’s common stock. Share-based compensation expense is measured by the market value of the Company’s stock on the date of grant. Awards granted to non-employee directors under the 2017 Plan prior to the June 2020 grant vest in three equal installments on the first, second and third anniversaries of the grant date, while restricted shares granted under the 2020 Plan on and subsequent to June 2020 will vest on the first anniversary of such grant date, or earlier subject to retirement eligibility . In addition, effective in the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires. Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. In the first quarter of 2021, it was determined that the performance stock awards that were granted in 2018 were not earned and, accordingly, those shares were forfeited. During the three months ended March 31, 2021, $1.3 million was included in selling, general and administrative expenses related to share-based payments, and a net of 317,605 shares of common stock were issued upon the vesting of restricted stock. During the three months ended March 31, 2020, $0.9 million was included in selling, general and administrative expenses related to share-based payments, and a net of 221,492 shares of common stock were issued upon the vesting of restricted stock.

SEGMENT DATA

SEGMENT DATA	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
SEGMENT DATA	SEGMENT DATA In the first quarter of 2021, the Company modified its disclosures of reportable segments to better align with its management structure and to reflect how the operating results are regularly reviewed by the chief operating decision maker. As a result, the two reportable segments now are Nurse and Allied Staffing and Physician Staffing, and the results of the Search segment have been consolidated within Nurse and Allied Staffing for all periods presented. The Company’s segments offer services to its customers as described below: ● Nurse and Allied Staffing – Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel and local branch-based nurse and allied professionals, managed services programs (MSP) services, education healthcare services, and outsourcing services. In addition, Nurse and Allied Staffing provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. Its clients include: public and private acute-care and non-acute care hospitals, government facilities, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States. ● Physician Staffing – Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The Company evaluates performance of each segment primarily based on revenue and contribution income. The Company defines contribution income as income or loss from operations before depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlement charges, impairment charges, and corporate overhead. Contribution income is a financial measure used by the Company when assessing segment performance and is provided in accordance with the Segment Reporting Topic of the FASB ASC. The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments’ internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments. Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows: Three Months Ended March 31, 2021 2020 (amounts in thousands) Revenue from services: Nurse and Allied Staffing $ 313,008 $ 191,883 Physician Staffing 16,233 18,181 $ 329,241 $ 210,064 Contribution income: Nurse and Allied Staffing $ 37,417 $ 13,822 Physician Staffing 1,428 631 38,845 14,453 Corporate overhead (a) 14,211 11,270 Depreciation and amortization 2,253 3,296 Acquisition and integration-related costs — 77 Restructuring costs 1,238 564 Impairment charges 149 — Income (loss) from operations $ 20,994 $ (754) _______________ (a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).

CONTINGENCIES

CONTINGENCIES	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES Legal Proceedings From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These matters primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. For these matters, the Company has established a liability of $0.8 million as of March 31, 2021. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company's current assessments, including available insurance recoveries, which would impact the Company's profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company's financial results. In October 2019, the Company received a grand jury subpoena directed to Advantage On Call, the assets of which were purchased by Cross Country Healthcare, Inc. in 2017. The subpoena related to an investigation of healthcare staffing services. On March 30, 2021, a former employee of VDA OC, and VDA OC were indicted on conspiracy charges in violation of antitrust laws. The conduct charged in the indictment involves events that occurred prior to the Cross Country Healthcare, Inc. acquisition of certain assets from VDA OC (formerly known as Advantage On Call) and that do not involve Cross Country Healthcare or any of its executives, subsidiaries, or divisions. The Company believes the outcome of any outstanding loss contingencies as of March 31, 2021 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows. Sales and Other State Non-Income Tax Liabilities

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three months ended March 31, 2021 and 2020, the Company calculated its effective tax rate based on year-to-date results, pursuant to the Income Taxes Topic of the FASB ASC. The Company’s effective tax rate for the three months ended March 31, 2021 and 2020 was 4.5% and negative 11.2%, respectively, which included immaterial discrete items. As a result of the Company's valuation allowance on substantially all of its domestic deferred tax assets, income tax expense for the three months ended March 31, 2021 and 2020 was primarily impacted by international and state taxes. As of March 31, 2021 and December 31, 2020, the Company had a valuation allowance of $32.4 million and $37.5 million, respectively. The valuation allowance was recorded against all domestic deferred tax assets not more likely than not to be realized. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support its reversal. As of March 31, 2021, the Company had approximately $1.0 million of unrecognized tax benefits included in other long-term liabilities, $7.4 million, net of deferred taxes, which would affect the effective tax rate if recognized. During the three months ended March 31, 2021, the Company had gross increases of $0.3 million to its current year unrecognized tax benefits related to federal and state tax positions. The tax years 2012 through 2020 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Prior to December 31, 2020, the Company had a 68% ownership interest in Cross Country Talent Acquisition Group, LLC, a joint venture between the Company and a hospital system. The Company generated revenue providing staffing services to the hospital system of $5.6 million for the three months ended March 31, 2020. At December 31, 2020, the Company had a receivable balance of $1.7 million and a payable balance of $0.2 million. Effective December 31, 2020, the sole professional staffing services agreement held by its joint venture was terminated, at which time the Company entered into a direct staffing agreement with the hospital system. The Company expects to dissolve Cross Country Talent Acquisition Group, LLC during 2021. The Company has entered into an arrangement for digital marketing services provided by a firm that is related to Mr. Clark, the Company's Co-Founder & Chief Executive Officer. Mr. Clark is a minority shareholder in the firm's parent company and is a member of the parent company's Board of Directors. Management believes the terms of the arrangement are equivalent to those prevailing in an arm's-length transaction and have been approved by the Company through its related party process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three months ended March 31, 2021 and 2020, the Company incurred an immaterial amount in expenses related to these fees. At March 31, 2021, the Company had an immaterial payable balance due to this entity, and no payable balance at December 31, 2020. Mark Fortunato is employed by the Company as Vice President of Corporate Development. He is the son-in-law of Kevin C. Clark, Co-Founder & Chief Executive Officer of the Company. Mr. Fortunato’s compensation and benefits are comparable to those generally available to similarly situated employees. In the first quarter of 2020, the Company entered into a note payable of $7.3 million related to contingent consideration assumed as part of a prior period acquisition, payable in three equal installments. The payees of the note are controlled by an employee of the sellers who remained with the Company. The first two installments have been paid, leaving a note payable balance of $2.5 million at March 31, 2021.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS On March 12, 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. When elected, the optional expedients for contract modifications must be applied consistently for all eligible contracts or transactions. On January 7, 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848), Scope , to refine the scope of guidance on reference rate reform to apply to derivatives that are affected by the discounting transition. The amendments in these updates are effective as of March 12, 2020 through December 31, 2022. As of March 31, 2021, the Company is not impacted by this guidance; however, it will continue to assess the potential impact on its debt contracts and future hedging relationships, if applicable, through the effective period.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Consolidation	The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company), as well as Cross Country Talent Acquisition Group, LLC, which was a joint venture controlled by the Company but not wholly-owned. Effective December 31, 2020, the sole pr ofessional staffing services agreement held by this joint venture was terminated and, as a result, the Company expects to dissolve Cross Country Talent Acquisition Group, LLC during fiscal 2021. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These adjustments consisted of all normal recurring items.
Basis of Accounting	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by United States generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K as filed with the SEC on February 25, 2021 (2020 Form 10-K). The December 31, 2020 condensed consolidated balance sheet included herein was derived from the December 31, 2020 audited consolidated balance sheet included in the 2020 Form 10-K. Certain prior year amounts have been reclassified to conform to the current year presentation. See condensed consolidated statements of cash flows, Note 3 - Revenue Recognition, and Note 11 - Segment Data.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context of the unknown future impacts of the current global outbreak of COVID-19
Accounts Receivable, net	Accounts Receivable, net The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors’ time worked but not yet billed at March 31, 2021 and December 31, 2020 totaled $92.2 million and $48.3 million, respectively. The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable and contract assets based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered current expectations of future economic conditions, including the impact of COVID-19, when estimating its allowance for doubtful accounts. The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: Three Months Ended March 31, 2021 2020 Allowance for Doubtful Accounts (amounts in thousands) Balance at beginning of period $ 3,416 $ 2,406 Bad Debt Expense 504 539 Write-Offs, net of Recoveries (699) (349) Balance at end of period 3,221 2,596 In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The balance of this allowance as of March 31, 2021 and December 31, 2020 was $0.7 million and $0.6 million, respectively.
Restructuring Costs	Restructuring Costs The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations primarily include employee termination costs and lease-related exit costs.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The guidance requires either a prospective, retrospective, or modified retrospective approach depending on the amendment. The Company prospectively adopted this guidance with no material impact on its consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts	The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: Three Months Ended March 31, 2021 2020 Allowance for Doubtful Accounts (amounts in thousands) Balance at beginning of period $ 3,416 $ 2,406 Bad Debt Expense 504 539 Write-Offs, net of Recoveries (699) (349) Balance at end of period 3,221 2,596
Restructuring and Related Costs	Reconciliation of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below: Employee Termination Costs Lease-Related Exit Costs (amounts in thousands) Balance at January 1, 2021 $ 499 $ 2,687 Charged to restructuring costs (a) 824 46 Payments (344) (207) Balance at March 31, 2021 979 2,526 ________________ (a) Aside from what is presented in the table above, restructuring costs in the condensed consolidated statements of operations for the three months ended March 31, 2021 include $0.4 million of ongoing lease costs related to the Company's strategic reduction in its real estate footprint which are included as operating lease liabilities - current and non-current in our condensed consolidated balance sheets. Other costs were immaterial for the three months ended March 31, 2021.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Three Months ended March 31, 2021 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 305,975 $ 15,406 $ 321,381 Other Services 7,033 827 7,860 Total $ 313,008 $ 16,233 $ 329,241 Three Months ended March 31, 2020 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 184,949 $ 17,160 $ 202,109 Other Services 6,934 1,021 7,955 Total $ 191,883 $ 18,181 $ 210,064

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share	The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended March 31, 2021 2020 (amounts in thousands, except per share data) Numerator: Net income (loss) attributable to common shareholders - Basic and Diluted $ 19,448 $ (2,089) Denominator: Weighted average common shares - Basic 36,181 35,873 Effect of diluted shares: Share-based awards (a) 853 — Weighted average common shares - Diluted 37,034 35,873 Net income (loss) per share attributable to common shareholders - Basic $ 0.54 $ (0.06) Net income (loss) per share attributable to common shareholders - Diluted $ 0.53 $ (0.06) ________________ (a) Due to the net loss for the three months ended March 31, 2020, 454,920 shares were excluded from diluted weighted average shares due to their anti-dilutive effect.

GOODWILL, TRADE NAMES, AND OT_2

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Acquired Intangible Assets	The Company had the following acquired intangible assets: March 31, 2021 December 31, 2020 Gross Accumulated Net Gross Accumulated Net (amounts in thousands) Intangible assets subject to amortization: Databases $ 30,530 $ 16,085 $ 14,445 $ 30,530 $ 15,322 $ 15,208 Customer relationships 33,538 14,719 18,819 33,538 14,007 19,531 Non-compete agreements 304 227 77 304 212 92 Trade names — — — — — — Other intangible assets, net $ 64,372 $ 31,031 $ 33,341 $ 64,372 $ 29,541 $ 34,831 Intangible assets not subject to amortization: Trade names, indefinite-lived $ 5,900 $ 5,900
Estimated Annual Amortization Expense	As of March 31, 2021, estimated annual amortization expense is as follows: Years Ending December 31: (amounts in thousands) 2021 $ 4,473 2022 5,933 2023 5,875 2024 5,238 2025 4,679 Thereafter 7,143 $ 33,341
Schedule of Goodwill	The changes in the carrying amount of goodwill by reportable segment are as follows: Nurse and Physician Total (amounts in thousands) Balances as of December 31, 2020 Aggregate goodwill acquired $ 367,880 $ 43,405 $ 411,285 Sale of business (9,889) — (9,889) Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss 88,117 2,807 90,924 Balances as of March 31, 2021 Aggregate goodwill acquired 367,880 43,405 411,285 Sale of business (9,889) — (9,889) Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss $ 88,117 $ 2,807 $ 90,924 ________________

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Supplemental Balance Sheet Information	The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets: Classification on Condensed Consolidated Balance Sheets: March 31, 2021 December 31, 2020 (amounts in thousands) Operating lease right-of-use assets $ 9,835 $ 10,447 Operating lease liabilities - current $ 4,803 $ 4,509 Operating lease liabilities - non-current $ 13,978 $ 15,234 March 31, 2021 December 31, 2020 Weighted-average remaining lease term 3.9 years 4.1 years Weighted average discount rate 6.36 % 6.32 %
Operating Lease Maturity	The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2021: Years Ending December 31: (amounts in thousands) 2021 $ 4,413 2022 5,381 2023 5,048 2024 3,687 2025 2,716 Total minimum lease payments 21,245 Less: amount of lease payments representing interest (2,464) Present value of future minimum lease payments 18,781 Less: operating lease liabilities - current (4,803) Operating lease liabilities - non-current $ 13,978
Lease Costs	The table below provides information regarding supplemental cash flows: Three Months Ended March 31, 2021 2020 (amounts in thousands) Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of operating lease liabilities $ 1,637 $ 1,835 Right-of-use assets acquired under operating lease $ — $ 500 The components of lease expense are as follows: Three Months Ended March 31, 2021 2020 (amounts in thousands) Amounts Included in Condensed Consolidated Statements of Operations: Operating lease expense $ 914 $ 1,523 Short-term lease expense $ 849 $ 1,845 Variable and other lease costs $ 468 $ 574

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis	The estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis is as follows: Fair Value Measurements March 31, 2021 December 31, 2020 (amounts in thousands) Financial Assets: (Level 1) Deferred compensation asset $ 1,204 $ 1,156 Financial Liabilities: (Level 1) Deferred compensation liability $ 2,553 $ 2,475
Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value	The carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value are as follows: March 31, 2021 December 31, 2020 Carrying Fair Carrying Fair Financial Liabilities: (amounts in thousands) (Level 2) Note Payable $ 2,426 $ 2,426 $ 4,851 $ 4,851 Senior Secured Asset-Based Loan $ 96,025 $ 96,025 $ 53,408 $ 53,408

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Restricted Stock Activity	The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the three months ended March 31, 2021: Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2021 1,345,819 $ 7.04 548,151 $ 7.64 Granted 384,871 $ 12.49 160,416 $ 12.49 Vested (479,793) $ 7.34 — $ — Forfeited (37,814) $ 6.95 (125,523) $ 10.24 Unvested restricted stock awards, March 31, 2021 1,213,083 $ 8.65 583,044 $ 8.41

SEGMENT DATA (Tables)

SEGMENT DATA (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Information on Operating Segments and Reconciliation to Loss From Operations	Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows: Three Months Ended March 31, 2021 2020 (amounts in thousands) Revenue from services: Nurse and Allied Staffing $ 313,008 $ 191,883 Physician Staffing 16,233 18,181 $ 329,241 $ 210,064 Contribution income: Nurse and Allied Staffing $ 37,417 $ 13,822 Physician Staffing 1,428 631 38,845 14,453 Corporate overhead (a) 14,211 11,270 Depreciation and amortization 2,253 3,296 Acquisition and integration-related costs — 77 Restructuring costs 1,238 564 Impairment charges 149 — Income (loss) from operations $ 20,994 $ (754) _______________ (a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unbilled contracts receivable	$ 92.2	$ 48.3
Sales allowance, billing-related adjustments	$ 0.7	$ 0.6
Customer Concentration Risk | Accounts Receivable | Major Customer | Nurse And Allied Staffing
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, percentage	12.00%
Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Threshold period, past due for payment of services provided	60 days
Minimum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Threshold period, past due for payment of services provided	30 days

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Allowance for Doubtful Accounts
Balance at beginning of period	$ 3,416	$ 2,406
Bad debt expense	504	539
Write-Offs, net of Recoveries	(699)	(349)
Balance at end of period	$ 3,221	$ 2,596

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring Reserve [Roll Forward]
Charged to restructuring costs	$ 1,238	$ 564
Restructuring costs	1,238	$ 564
Employee Termination Costs
Restructuring Reserve [Roll Forward]
Balance at January 1, 2021	499
Charged to restructuring costs	824
Payments	(344)
Balance at March 31, 2021	979
Restructuring costs	824
Lease-Related Exit Costs
Restructuring Reserve [Roll Forward]
Balance at January 1, 2021	2,687
Charged to restructuring costs	46
Payments	(207)
Balance at March 31, 2021	2,526
Restructuring costs	46
Strategic Reduction of Real Estate Footprint
Restructuring Reserve [Roll Forward]
Charged to restructuring costs	400
Restructuring costs	$ 400

REVENUE RECOGNITION - Disaggreg

REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Revenue from services	$ 329,241	$ 210,064
Temporary Staffing Services
Disaggregation of Revenue [Line Items]
Revenue from services	321,381	202,109
Other Services
Disaggregation of Revenue [Line Items]
Revenue from services	7,860	7,955
Nurse And Allied Staffing
Disaggregation of Revenue [Line Items]
Revenue from services	313,008	191,883
Nurse And Allied Staffing | Temporary Staffing Services
Disaggregation of Revenue [Line Items]
Revenue from services	305,975	184,949
Nurse And Allied Staffing | Other Services
Disaggregation of Revenue [Line Items]
Revenue from services	7,033	6,934
Physician Staffing
Disaggregation of Revenue [Line Items]
Revenue from services	16,233	18,181
Physician Staffing | Temporary Staffing Services
Disaggregation of Revenue [Line Items]
Revenue from services	15,406	17,160
Physician Staffing | Other Services
Disaggregation of Revenue [Line Items]
Revenue from services	$ 827	$ 1,021

REVENUE RECOGNITION - Additiona

REVENUE RECOGNITION - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)segment	Mar. 31, 2020USD ($)
Disaggregation of Revenue [Line Items]
Number of reportable segments | segment	2
Revenue from services	$ 329,241	$ 210,064
Nurse And Allied Staffing
Disaggregation of Revenue [Line Items]
Revenue from services	313,008	191,883
Nurse And Allied Staffing | Revision of Prior Period, Adjustment
Disaggregation of Revenue [Line Items]
Revenue from services		3,600
Other Services
Disaggregation of Revenue [Line Items]
Revenue from services	7,860	7,955
Other Services | Nurse And Allied Staffing
Disaggregation of Revenue [Line Items]
Revenue from services	$ 7,033	6,934
Other Services | Nurse And Allied Staffing | Revision of Prior Period, Adjustment
Disaggregation of Revenue [Line Items]
Revenue from services		$ 3,600

COMPREHENSIVE INCOME (LOSS) (De

COMPREHENSIVE INCOME (LOSS) (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Loss on currency fluctuations	$ 1.3	$ 1.3

EARNINGS PER SHARE - Components

EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net income (loss) attributable to common shareholders - Basic and Diluted	$ 19,448	$ (2,089)
Denominator:
Weighted average common shares - Basic (shares)	36,181	35,873
Effect of diluted shares:
Share-based awards (shares)	853	0
Weighted average common shares - Diluted (shares)	37,034	35,873
Net income (loss) per share attributable to common shareholders - Basic (in dollars per share)	$ 0.54	$ (0.06)
Net income (loss) per share attributable to common shareholders - Diluted (in dollars per share)	$ 0.53	$ (0.06)

EARNINGS PER SHARE - Additional

EARNINGS PER SHARE - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020shares
Earnings Per Share [Abstract]
Shares excluded from diluted weighted average shares (shares)	454,920

GOODWILL, TRADE NAMES, AND OT_3

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 64,372	$ 64,372
Accumulated Amortization	31,031	29,541
Intangible assets subject to amortization, net carrying amount	33,341	34,831
Trade names, indefinite-lived	5,900	5,900
Databases
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	30,530	30,530
Accumulated Amortization	16,085	15,322
Intangible assets subject to amortization, net carrying amount	14,445	15,208
Customer relationships
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	33,538	33,538
Accumulated Amortization	14,719	14,007
Intangible assets subject to amortization, net carrying amount	18,819	19,531
Non-compete agreements
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	304	304
Accumulated Amortization	227	212
Intangible assets subject to amortization, net carrying amount	77	92
Trade names
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	0	0
Accumulated Amortization	0	0
Intangible assets subject to amortization, net carrying amount	$ 0	$ 0

GOODWILL, TRADE NAMES, AND OT_4

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Annual Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 4,473
2022	5,933
2023	5,875
2024	5,238
2025	4,679
Thereafter	7,143
Intangible assets subject to amortization, net carrying amount	$ 33,341	$ 34,831

GOODWILL, TRADE NAMES, AND OT_5

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Goodwill Rollforward (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Aggregate goodwill acquired	$ 411,285	$ 411,285
Accumulated impairment loss, beginning balance	(310,472)	(310,472)
Goodwill, net of impairment loss	90,924	90,924
Sale of business
Goodwill [Roll Forward]
Aggregate goodwill acquired	9,889	9,889
Nurse And Allied Staffing
Goodwill [Roll Forward]
Aggregate goodwill acquired	367,880	367,880
Accumulated impairment loss, beginning balance	(269,874)	(269,874)
Goodwill, net of impairment loss	88,117	88,117
Nurse And Allied Staffing | Sale of business
Goodwill [Roll Forward]
Aggregate goodwill acquired	9,889	9,889
Physician Staffing
Goodwill [Roll Forward]
Aggregate goodwill acquired	43,405	43,405
Accumulated impairment loss, beginning balance	(40,598)	(40,598)
Goodwill, net of impairment loss	2,807	2,807
Physician Staffing | Sale of business
Goodwill [Roll Forward]
Aggregate goodwill acquired	$ 0	$ 0

GOODWILL, TRADE NAMES, AND OT_6

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details) $ / shares in Units, $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2021segment	Mar. 31, 2020USD ($)$ / shares	Dec. 31, 2020USD ($)	Dec. 31, 2019
Goodwill [Line Items]
Number of reportable segments | segment	2
Trade names
Goodwill [Line Items]
Weighted average amortization period if not accelerated				7 years 6 months
Impact of accelerated amortization on earnings per share (in dollars per share) | $ / shares		$ 0.02
Accelerated Amortization | Trade names
Goodwill [Line Items]
Amortization of intangible assets | $		$ 0.7	$ 2.9

DEBT - 2019 ABL Credit Agreemen

DEBT - 2019 ABL Credit Agreement (Details) - USD ($)	Mar. 31, 2021	Oct. 25, 2019	Mar. 31, 2021	Mar. 08, 2021	Dec. 31, 2020	Jun. 30, 2020
Line of Credit Facility [Line Items]
Line of credit, carrying amount	$ 96,025,000		$ 96,025,000		$ 53,408,000
Senior Secured Asset-Based Loan
Line of Credit Facility [Line Items]
Line of credit term		5 years
Maximum borrowing capacity	150,000,000	$ 120,000,000	150,000,000	$ 150,000,000		$ 130,000,000
Borrowing base, percentage of assets		85.00%
Line of credit, carrying amount	96,000,000		96,000,000
Letters of credit outstanding	18,500,000		18,500,000
Borrowing availability	$ 35,500,000		$ 35,500,000
Weighted average interest rate	2.46%		2.46%		2.73%
Quarterly commitment fee on the average daily unused portion (percent)			0.375%
Senior Secured Asset-Based Loan | LIBOR
Line of Credit Facility [Line Items]
Interest margin (percent)	2.00%
Senior Secured Asset-Based Loan | Base Rate
Line of Credit Facility [Line Items]
Interest margin (percent)	1.00%
Senior Secured Asset-Based Loan, Supplemental Activities Lending | LIBOR
Line of Credit Facility [Line Items]
Interest margin (percent)	4.00%
Senior Secured Asset-Based Loan, Supplemental Activities Lending | Base Rate
Line of Credit Facility [Line Items]
Interest margin (percent)	3.00%
Swingline Sublimit | Senior Secured Asset-Based Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 15,000,000
Standby Letters Of Credit Sublimit | Senior Secured Asset-Based Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 35,000,000

DEBT - Notes Payable (Details)

DEBT - Notes Payable (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)installment
Debt Instrument [Line Items]
Payment of notes payable	$ 2,425	$ 0
Earnout Notes Payable
Debt Instrument [Line Items]
Notes payable	2,500	$ 7,300
Number of installments | installment		3
Payment of notes payable	$ 2,400

LEASES - Balance Sheet Informat

LEASES - Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease right-of-use assets	$ 9,835	$ 10,447
Operating lease liabilities - current	4,803	4,509
Operating lease liabilities - non-current	$ 13,978	$ 15,234
Weighted-average remaining lease term	3 years 10 months 24 days	4 years 1 month 6 days
Weighted average discount rate	6.36%	6.32%

LEASES - Undiscounted Cash Flow

LEASES - Undiscounted Cash Flows (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2021	$ 4,413
2022	5,381
2023	5,048
2024	3,687
2025	2,716
Total minimum lease payments	21,245
Less: amount of lease payments representing interest	(2,464)
Present value of future minimum lease payments	18,781
Less: operating lease liabilities - current	(4,803)	$ (4,509)
Operating lease liabilities - non-current	$ 13,978	$ 15,234

LEASES - Other Information (Det

LEASES - Other Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 1,637	$ 1,835
Right-of-use assets acquired under operating lease	0	500
Operating lease expense	914	1,523
Short-term lease expense	849	1,845
Variable and other lease costs	$ 468	$ 574

FAIR VALUE MEASUREMENTS - Estim

FAIR VALUE MEASUREMENTS - Estimated Fair values Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Inputs, Level 1 - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Investment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation asset	$ 1,204	$ 1,156
Deferred compensation liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation liability	$ 2,553	$ 2,475

FAIR VALUE MEASUREMENTS - Finan

FAIR VALUE MEASUREMENTS - Financial Instrument that were not Measured at Fair Value (Details) - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Senior Secured Asset-Based Loan | Carrying Amount
Fair Value, Option, Quantitative Disclosures [Line Items]
Line of credit, fair value	$ 96,025	$ 53,408
Senior Secured Asset-Based Loan | Fair Value
Fair Value, Option, Quantitative Disclosures [Line Items]
Line of credit, fair value	96,025	53,408
Earnout Notes Payable | Carrying Amount
Fair Value, Option, Quantitative Disclosures [Line Items]
Note payable, fair value	2,426	4,851
Earnout Notes Payable | Fair Value
Fair Value, Option, Quantitative Disclosures [Line Items]
Note payable, fair value	$ 2,426	$ 4,851

STOCKHOLDERS' EQUITY - Narrativ

STOCKHOLDERS' EQUITY - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)installmentshares	Mar. 31, 2020USD ($)shares	May 19, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares left remaining to repurchase under the plan (up to) (in shares)	510,004
Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for share-based payments (in shares)			3,000,000
Omnibus Plan | Member of the Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of vesting installments | installment	3
Minimum | Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested in period, net (in shares)	317,605	221,492
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation | $	$ 1.3	$ 0.9
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares repurchased and retired (in shares)	0	0

STOCKHOLDERS' EQUITY - Summary

STOCKHOLDERS' EQUITY - Summary of Restricted Stock and Performance Shares (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Restricted Stock Awards
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) | shares	1,345,819
Granted (in shares) | shares	384,871
Vested (in shares) | shares	(479,793)
Forfeited (in shares) | shares	(37,814)
Unvested restricted stock awards, Ending balance (in shares) | shares	1,213,083
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) | $ / shares	$ 7.04
Granted (in dollars per share) | $ / shares	12.49
Vested (in dollars per share) | $ / shares	7.34
Forfeited (in dollars per share) | $ / shares	6.95
Unvested restricted stock awards, Ending balance (in dollars per share) | $ / shares	$ 8.65
Performance Stock Awards
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) | shares	548,151
Granted (in shares) | shares	160,416
Vested (in shares) | shares	0
Forfeited (in shares) | shares	(125,523)
Unvested restricted stock awards, Ending balance (in shares) | shares	583,044
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) | $ / shares	$ 7.64
Granted (in dollars per share) | $ / shares	12.49
Vested (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	10.24
Unvested restricted stock awards, Ending balance (in dollars per share) | $ / shares	$ 8.41

SEGMENT DATA - Narrative (Detai

SEGMENT DATA - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)segment	Mar. 31, 2020USD ($)
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Number of operating segments | segment	2
Revenue from services	$ 329,241	$ 210,064
Contribution income (loss)	38,845	14,453
Nurse And Allied Staffing
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services	313,008	191,883
Contribution income (loss)	$ 37,417	13,822
Nurse And Allied Staffing | Revision of Prior Period, Adjustment
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services		3,600
Contribution income (loss)		$ 300

SEGMENT DATA - Information on O

SEGMENT DATA - Information on Operating Segments and Reconciliation to Loss From Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services	$ 329,241	$ 210,064
Contribution income (loss)	38,845	14,453
Corporate overhead	14,211	11,270
Depreciation and amortization	2,253	3,296
Acquisition and integration-related costs	0	77
Restructuring costs	1,238	564
Impairment charges	149	0
Income (loss) from operations	20,994	(754)
Nurse And Allied Staffing
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services	313,008	191,883
Contribution income (loss)	37,417	13,822
Physician Staffing
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services	16,233	18,181
Contribution income (loss)	$ 1,428	$ 631

CONTINGENCIES (Details)

CONTINGENCIES (Details) $ in Millions	Mar. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Contingent liability	$ 0.8

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	4.50%	(11.20%)
Valuation allowance	$ 32.4		$ 37.5
Unrecognized tax benefits	1
Unrecognized tax benefits that would impact effective tax rate	7.4
Gross increase to current year unrecognized tax benefits related to federal and state tax issues	$ 0.3

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	3 Months Ended
	Mar. 31, 2020USD ($)installment	Mar. 31, 2021USD ($)installment	Dec. 31, 2020USD ($)	Dec. 30, 2020
Earnout Notes Payable
Related Party Transaction [Line Items]
Notes payable	$ 7,300,000	$ 2,500,000
Number of installments | installment	3
Number of installments paid | installment		2
Cross Country Talent Acquisition Group, LLC
Related Party Transaction [Line Items]
Joint venture, percent ownership				68.00%
Revenue from related parties	$ 5,600,000
Receivable balance with joint venture			$ 1,700,000
Payable balance with joint venture			200,000
Chief Executive Officer
Related Party Transaction [Line Items]
Payable balance with joint venture		$ 0	$ 0